Donald Bobo Jr Sells 24,000 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 24,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the completion of the sale, the vice president owned 21,266 shares of the company’s stock, valued at $1,782,941.44. This trade represents a 53.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Edwards Lifesciences Stock Up 2.9%

Shares of EW traded up $2.43 during mid-day trading on Thursday, hitting $85.83. 3,707,770 shares of the company’s stock were exchanged, compared to its average volume of 5,066,583. The stock has a market cap of $49.81 billion, a price-to-earnings ratio of 46.90, a P/E/G ratio of 2.18 and a beta of 0.94. The firm has a fifty day moving average of $82.70 and a two-hundred day moving average of $81.13. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the prior year, the company posted $0.59 earnings per share. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Brighton Jones LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth $266,000. Focus Partners Advisor Solutions LLC boosted its stake in shares of Edwards Lifesciences by 20.3% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 8,888 shares of the medical research company’s stock valued at $695,000 after purchasing an additional 1,499 shares in the last quarter. Oppenheimer Asset Management Inc. grew its holdings in shares of Edwards Lifesciences by 10.9% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 24,060 shares of the medical research company’s stock worth $1,882,000 after purchasing an additional 2,361 shares during the last quarter. Wealthfront Advisers LLC increased its position in shares of Edwards Lifesciences by 10.3% during the 2nd quarter. Wealthfront Advisers LLC now owns 27,579 shares of the medical research company’s stock worth $2,157,000 after purchasing an additional 2,566 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in Edwards Lifesciences by 90.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 200,964 shares of the medical research company’s stock valued at $15,717,000 after purchasing an additional 95,606 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on EW. Piper Sandler reaffirmed an “overweight” rating and set a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Robert W. Baird set a $90.00 target price on shares of Edwards Lifesciences in a research report on Monday, January 12th. Evercore restated an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a report on Monday, January 5th. Barclays reiterated an “overweight” rating and issued a $104.00 price objective (up from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Finally, Canaccord Genuity Group set a $87.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, December 17th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $96.14.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.